Jason Rhodes is a partner and focuses on creating and building novel therapeutics companies.
Jason is the chairman and was the founding CEO of Generation Bio (NASDAQ: GBIO), Dyne Therapeutics (NASDAQ: DYN), and Rectify Pharmaceuticals. He is also on the boards of Replimune (NASDAQ: REPL), Third Harmonic Bio, Be Biopharma, K36, Accent Therapeutics, and Gemini Therapeutics (NASDAQ: GMTX). He was the chairman and founding CEO of Disarm Therapeutics, acquired by Eli Lilly in 2020, and was previously on the board of Bicycle Therapeutics (NASDAQ: BCYC).
Previously, Jason held leadership positions at Epizyme (NASDAQ: EPZM), where he was President and built the company from early stage research into the clinic and through a successful IPO in 2013, and at Alnylam Pharmaceuticals (NASDAQ: ALNY), where he led business development. Jason was also a founder and partner with Fidelity Biosciences (now F-Prime Capital), the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including FoldRx, acquired by Pfizer.
Jason received his BA from Yale University and his MBA from the Wharton School of the University of Pennsylvania.
He is a member of the advisory board of the Harvard Institute for RNA Medicine, the Blavatnik Fund at Yale University, and the Berklee College of Music Presidential Advisory Council. Jason spends his free time mountain biking and loudly watching Spanish fútbol with his family.